Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.88B |
| 2 |
Pfizer
PFE
|
+$1.41B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.17B |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.21B |
| 2 |
Adobe
ADBE
|
+$1.06B |
| 3 |
Stryker
SYK
|
+$955M |
| 4 |
Boston Scientific
BSX
|
+$695M |
| 5 |
Banco Santander
SAN
|
+$684M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
iShares US Energy ETF
IYE
$1.74B
| $309K | ﹤0.01% |
+4,774
| New | +$271K |
|
902
iShares Russell Top 200 Growth ETF
IWY
$15.9B
| $303K | ﹤0.01% |
1,219
-1,938
| -61% | -$513K |
|
903
Rithm Capital
RITM
$5.52B
| $303K | ﹤0.01% |
+31,914
| New | +$334K |
|
904
Cincinnati Financial
CINF
$27.3B
| $298K | ﹤0.01% |
1,893
-1,537
| -45% | -$250K |
|
905
Vanguard Short-Term Bond ETF
BSV
$44.7B
| $297K | ﹤0.01% |
3,785
-3,483
| -48% | -$274K |
|
906
Delta Air Lines
DAL
$57.5B
| $294K | ﹤0.01% |
4,426
-485
| -10% | -$32.7K |
|
907
First Trust Preferred Securities and Income ETF
FPE
$6.32B
| $291K | ﹤0.01% |
+16,376
| New | +$298K |
|
908
Dimensional US Targeted Value ETF
DFAT
$14.6B
| $290K | ﹤0.01% |
4,637
+1,240
| +37% | +$78.8K |
|
909
Targa Resources
TRGP
$58B
| $289K | ﹤0.01% |
1,151
-699
| -38% | -$152K |
|
|
FAX
910
DELISTED
abrdn Asia-Pacific Income Fund
FAX
| $287K | ﹤0.01% |
19,893
+2,462
| +14% | +$38.1K |
|
911
Fidelity High Dividend ETF
FDVV
$10.1B
| $287K | ﹤0.01% |
+5,190
| New | +$299K |
|
912
Diageo
DEO
$49B
| $284K | ﹤0.01% |
3,813
+845
| +28% | +$73.7K |
|
913
NXP Semiconductors
NXPI
$57.8B
| $284K | ﹤0.01% |
1,440
-299
| -17% | -$66.2K |
|
914
Apollo Global Management
APO
$72.4B
| $283K | ﹤0.01% |
2,539
-1,254
| -33% | -$155K |
|
915
Capital Group Dividend Value ETF
CGDV
$37.7B
| $283K | ﹤0.01% |
6,650
-4,260
| -39% | -$189K |
|
916
iShares ESG Aware US Aggregate Bond ETF
EAGG
$4.96B
| $280K | ﹤0.01% |
5,891
+674
| +13% | +$32.3K |
|
917
Amdocs
DOX
$5.92B
| $280K | ﹤0.01% |
4,286
-228
| -5% | -$16.7K |
|
918
MetLife
MET
$61.9B
| $279K | ﹤0.01% |
3,939
-1,533
| -28% | -$115K |
|
919
Zoetis
ZTS
$32.4B
| $277K | ﹤0.01% |
2,344
-631
| -21% | -$78K |
|
920
Welltower
WELL
$169B
| $277K | ﹤0.01% |
1,400
-310
| -18% | -$61.3K |
|
921
NetApp
NTAP
$35B
| $275K | ﹤0.01% |
2,688
-1,091
| -29% | -$111K |
|
922
Weyerhaeuser
WY
$18B
| $272K | ﹤0.01% |
11,119
-652
| -6% | -$16.4K |
|
923
iShares Core S&P US Value ETF
IUSV
$27.2B
| $269K | ﹤0.01% |
2,633
-1,628
| -38% | -$171K |
|
|
XYZ
924
Block Inc
XYZ
$48.4B
| $264K | ﹤0.01% |
4,381
-401
| -8% | -$24.4K |
|
925
Evolv Technologies
EVLV
$995M
| $263K | ﹤0.01% |
+43,546
| New | +$255K |
|
Similar funds
Ken Fisher's Q1 2026 Portfolio in Review
As of Q1 2026, Ken Fisher held 1,133 positions worth $295B, up 0.65% from $293B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Ken Fisher's Q1 2026 filing shows 116 new, 416 increased, 461 reduced and 117 closed positions. Its largest new stake was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M. The largest sale was Abbott, an estimated $1.21B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
- Ken Fisher's largest Q1 2026 buy was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M.
- Ken Fisher added most to AbbVie in Q1 2026, an estimated $1.88B increase.
- Ken Fisher's biggest Q1 2026 reduction was Abbott, cutting an estimated $1.21B.
- Ken Fisher fully exited Trip.com Group in Q1 2026, selling an estimated $175M.
- Ken Fisher's ten largest holdings make up 33% of its $295B portfolio in Q1 2026.
- Ken Fisher opened 116 new positions and closed 117 in Q1 2026.
- Ken Fisher's portfolio value rose 0.65% quarter-over-quarter to $295B.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.